phenotypic descriptions. Studies using arbitrary nomenclature continue to be published, making cross-comparison and meta-analysis difficult. One goal of GAD is to standardize molecular nomenclature in the archival process by including official HUGO gene symbols. After this assignment, each record is annotated with links to molecular databases (LocusLink, GeneCards, HapMap, etc.) and reference databases (PubMed, CDC), among others. Once they are standardized, integrating association data with other molecular databases, data mining tools, annotation and future sources of molecular data (e.g., gene interactions, quantitative trait loci) can be done systematically. Moreover, crosscomparison and meta-analysis of studies becomes more efficient.
There are three main components of GAD: a web interface, Perl modules and the database, which uses the Oracle RDBMS. The database has three layers; gene and disease data are organized into a large fact table in a middle layer with dimensional views on the top layer. The bottom layer contains the tools for adding, editing, batch loading and downloading data to and from the database.
We identify data fields common to genetic association studies, such as disease phenotypes, sample sizes, significance values, population information and allele descriptions. These fields are grouped into five views relevant to disease phenotypes (Disease View), gene-based molecular data (Gene View), chromosomal and mutation information (CH-SNP-Hap View), Reference View and All View. Table 1 shows a summary of the current contents in the database.
Query tools include key-word-search functions that permit field-specific searches, advanced combinatorial queries and pulldown selections of controlled vocabularies (Fig. 1) . Batch searches are done against an aggregate table, allowing the user to input a list of genes (300) at once. In this way, batch results from high-throughput assays, such as microarrays, proteomic, cDNA sequencing and SAGE (serial analysis of gene expression), can be rapidly queried in the context of human disease associations.
Of particular interest are phenotypic descriptions captured at multiple levels. A top level 'disease class' is assigned, followed by 'disease' from the original paper. To the editor:
The MMR system has evolved to increase the fidelity of DNA replication and homologous recombination 1 . MMR is also implicated in the processing of other types of DNA damage, as mammalian cells with defective MMR are tolerant to S N 1 type methylating agents such as N-methyl-N′-nitro-N-nitrosoguanidine and to 6-thioguanine and cisplatin 2 .
Reports describing the differential sensitivity of MMR-proficient and -deficient cells to ionizing radiation raised some controversy, as MMR-deficient cells were found to be slightly more resistant to ionizing radiation in some laboratories 3 but either equally 4 or less resistant 5 in others. The survival differences were also questioned, because MMR status was reported to affect the length of the G2-M checkpoint rather than cell viability 6 . A report by Brown et al. 7 has reopened this discussion by describing the requirement of a functional MMR system for activating the S-phase checkpoint and signaling of ionizing radiation-induced damage.
The aforementioned studies used matched MMR-proficient and -deficient mouse or human cell lines. Given that the establishment of these lines involved long periods of growth in cell culture, and that the MMR-deficient Is mismatch repair really required for ionizing radiation-induced DNA damage signaling?
C O R R E S P O N D E N C E
overt similarities at a clinical level, the genetic factors that contribute to those diseases may be shared at a molecular level 8, 9 . The development of a hierarchy of phenotypes, from broad to specific, may allow classification of diseases, subphenotypes and molecular parameters of disease and their relationship to complex traits.
GAD is an archive of published genetic association studies that provides a comprehensive, public, web-based repository of molecular, clinical and study parameters for >5,000 human genetic association studies at this time. This approach will allow the systematic analysis of complex common human genetic disease in the context of modern high-throughput assay systems and current annotated molecular nomenclature. 
